Wall Street Zen cut shares of Phibro Animal Health (NASDAQ:PAHC – Free Report) from a buy rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.
PAHC has been the subject of a number of other reports. Weiss Ratings lowered Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 10th. Three equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $46.50.
View Our Latest Stock Report on PAHC
Phibro Animal Health Price Performance
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.78 by $0.01. The business had revenue of $386.77 million for the quarter, compared to analysts’ expectations of $382.42 million. Phibro Animal Health had a return on equity of 35.88% and a net margin of 6.66%. As a group, research analysts predict that Phibro Animal Health will post 3.48 EPS for the current year.
Phibro Animal Health Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 16th. Investors of record on Wednesday, November 25th will be issued a $0.12 dividend. The ex-dividend date is Wednesday, November 25th. This represents a $0.48 dividend on an annualized basis and a yield of 1.4%. Phibro Animal Health’s dividend payout ratio is currently 19.12%.
Institutional Trading of Phibro Animal Health
A number of institutional investors have recently added to or reduced their stakes in PAHC. Engineers Gate Manager LP boosted its position in Phibro Animal Health by 112.8% during the second quarter. Engineers Gate Manager LP now owns 52,914 shares of the company’s stock worth $1,662,000 after purchasing an additional 28,052 shares during the period. Kings Path Partners LLC acquired a new stake in shares of Phibro Animal Health in the third quarter worth $613,000. Ranger Investment Management L.P. bought a new stake in shares of Phibro Animal Health during the 2nd quarter worth $9,182,000. Castleark Management LLC bought a new stake in shares of Phibro Animal Health during the 1st quarter worth $7,904,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Phibro Animal Health by 5.8% during the 1st quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock worth $31,899,000 after buying an additional 31,435 shares during the period. 99.34% of the stock is currently owned by institutional investors and hedge funds.
About Phibro Animal Health
Phibro Animal Health Corporation develops and markets products for animal health and nutrition. Its portfolio includes vaccines, medicated feed additives, and nutritional specialty products designed to support the health and productivity of livestock and other animals. The company also supplies trace minerals and related products used in animal nutrition and other applications. Its products serve markets including poultry, cattle, swine, and aquaculture, and are sold to customers in the United States and internationally.
See Also
- Five stocks we like better than Phibro Animal Health
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
